



## OvaScience Co-Founder Recognized in Boston Globe 100's "The Innovators" Feature

May 20, 2013

*Company also named among Boston's 50 on Fire*

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 20, 2013-- [OvaScience<sup>SM</sup>](#), (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that OvaScience Co-Founder Jonathan L. Tilly, Ph.D., has been named to *The Boston Globe's* 2013 "[The Innovators](#)" feature.

"Dr. Tilly revolutionized the way we think about fertility, and we are pleased that *The Boston Globe* has recognized his work as a driving force of innovation," said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. "His groundbreaking research, published on the cover of *Nature Medicine* last year, showed that women have egg precursor cells found in their ovaries that can mature into fresh, young eggs. OvaScience continues to work closely with Dr. Tilly to transform this exciting discovery into new treatments for the millions of women, couples and families affected by infertility worldwide."

On Sunday, May 19, for the twenty-fifth consecutive year, *The Boston Globe* unveiled its Globe 100 list, which ranks the best-performing public companies in Massachusetts. The third annual "The Innovators" feature, part of the [Globe 100](#), recognizes the most innovative people in Massachusetts who did the most in the past year to transform a business or their community in Massachusetts, ranging from technology pioneers to inspirational leaders in the nonprofit space. In 2011, OvaScience's Chief Scientific Officer, Scott Chappel, Ph.D., was [recognized](#) in the Globe 100's "The Innovators" feature for his influential role in multiple Boston start-ups.

Additionally, OvaScience was named among [BostInno's 50 on Fire](#), which features the top 50 game-changers and innovators across all industries in the Boston area. The winners of the award were announced during a celebration at the Courthouse in Boston.

### About OvaScience

OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company's patented technology is based on the discovery of egg precursor cells (EggPC<sup>SM</sup>), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, AUGMENT<sup>SM</sup> aims to improve egg quality and increase the success of in vitro fertilization (IVF). OvaScience's team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit [www.ovascience.com](http://www.ovascience.com).

### Forward-Looking Statements

*This press release includes forward-looking statements about the Company's strategy, future plans and prospects, including statements regarding the development of the Company's product candidates, including AUGMENT. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "aim," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates, which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.*

Source: OvaScience, Inc.

OvaScience, Inc.

Theresa McNeely, 617-299-7356

Head of Corporate Communications

[tmcneely@ovascience.com](mailto:tmcneely@ovascience.com)